ComparisonSeptember 10, 2026 · 2 min read

Ostarine vs RAD-140: What Preclinical Science and One Abandoned Trial Program Show

Research compounds for laboratory use only · not medical advice

The two most-searched SARMs compared on the only axes that hold up: receptor pharmacology, published human trial data (one has them, one doesn't), and what the enobosarm program's end tells researchers.

The two biggest names in the SARM aisle share a receptor and almost nothing else — least of all a human evidence base.

Pharmacology

Both are non-steroidal AR ligands; neither aromatizes (there’s no 17β-hydroxysteroid handle for aromatase to work with — the point of the class). The scaffold families differ: ostarine is the arylpropionamide prototype of the GTx program, RAD-140 the bicyclic aryl/quinuclidine design from the 2013 preclinical characterization (full AR selectivity comparison: Christiansen 2020 review). In direct binding work, RAD-140 is reported as the higher-affinity ligand — which is precisely the number marketing decks inflate into a dosing story it can’t support.

Evidence — the asymmetry is the article

Ostarine has human data, and it’s cautionary. Phase II in older adults: lean mass up, endogenous testosterone down dose-dependently (PMC3177038). The hip-fracture recovery program then halted after a mortality imbalance in the highest-dose arm — the single most-cited safety signal in the entire class.

RAD-140 has none. No registered completed human trials; everything published is design and preclinical characterization (Hwang 2013). “More potent in rats” is a legitimate research finding and an illegitimate human claim — the gap between those two sentences is the SARM market.

Analytical reality

Van Wagoner et al. (JAMA 2017) GC-MS/MS-audited 76 marketed “SARM” products: barely half matched their labels; unapproved pro-drug modifications (masked versions of S-4 and others) were discovered in the bottles themselves. If a study is buying “RAD-140” from a consumer channel, the independent variable may be an unknown compound. The research-grade response is batch COAs with mass data you can verify against the MW calculator — catalog pages: Ostarine, RAD-140, LGD-4033.

Research-use framing

Both compounds sit in the catalog as analytical reference materials for AR-pathway and doping-analysis research, at preclinical doses only, with the enobosarm outcome data stated on the page beside the CAS number. No dose here is a human recommendation; there are no human doses for this class.

For laboratory research use only. Not medical advice.

FAQ

Frequently asked questions

What is the main scientific difference between ostarine and RAD-140?

Scaffold and evidence depth. Ostarine (enobosarm) is an arylpropionamide with multiple completed human trials — the most-documented SARM pharmacologically. RAD-140 is a bicyclic aryl/quinuclidine design with published preclinical binding data but no completed human trials as of 2026.

Has either been approved?

Neither. Enobosarm's late-stage program in elderly muscle wasting ended after the hip-fracture studies, and the 25 mg/day arm showed a mortality imbalance that stopped further high-dose development. RAD-140 never entered the trial pipeline.

Which has more published research?

Ostarine, by a wide margin — phase II data in older adults showed lean-body-mass gain with dose-dependent testosterone suppression, plus the hip-fracture program literature. RAD-140's published profile is medicinal-chemistry and preclinical.

Why does the market still push RAD-140?

Because 'no human data' reads as 'potent' in marketing copy. The JAMA 2017 audit found much of what was sold as RAD-140 wasn't even RAD-140 — the product claims outran the analysis.

Keep reading

Guide

LGD-4033 (Ligandrol) Research Reference: The Human-Trial SARM With a Suppression Fine-Print

Ligandrol is one of few SARMs with published human-phase data — and that data is precisely what makes it a documentation-first research compound. Chemistry, trial record, and analytical specs.

Read

Comparison

Winstrol, Anavar or Dianabol: Oral Androgens Compared

Mechanism, molecular weight, half-life and research uses of stanozolol, oxandrolone and methandrostenolone — the three oral reference standards in the catalog.

Read

Guide

RAD-140 (Testolone) for Research Reference: Chemistry, Potency Data, and What the Absence of Human Trials Means

Testolone is the highest-affinity SARM in most published receptor panels — and has zero completed human trials. What preclinical science establishes, what it cannot, and how to spec it analytically.

Read

Laboratory tools